Brief: Clearside Biomedical Announces Advancement Of Xipere® In Asia-Pacific For Treatment Of Uveitic Macular Edema
04/10/2023 14:11
Oct 4 (Reuters) - Clearside Biomedical Inc CLSD.O :
* CLEARSIDE BIOMEDICAL ANNOUNCES ADVANCEMENT OF XIPERE® IN
ASIA-PACIFIC FOR SUPRACHOROIDAL TREATMENT OF UVEITIC MACULAR
EDEMA AS PARTNER ARCTIC VISION COMPLETES ENROLLMENT IN PHASE 3
CLINICAL TRIAL IN CHINA
* CLEARSIDE BIOMEDICAL INC - CONTINUED PROGRESS IN GLOBAL
DEVELOPMENT AND COMMERCIALIZATION OF XIPERE(®) (KNOWN AS
ARCATUS(®) IN CHINA)
Source text for Eikon: ID:nGNX4pQs1G
Further company coverage: CLSD.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Clearside Biomedical,
See all newsBrief: Clearside Biomedical Completes Financial Restructuring And Emerges From Chapter 11 With Steel Partners As Plan Sponsor
U.S. STOCKS ON THE MOVE-Merck, Genco, Tesla
U.S. STOCKS ON THE MOVE-Morgan Stanley, Merck, Genco
Clearside Biomedical plunges after filing for Chapter 11 bankruptcy
U.S. STOCKS ON THE MOVE-Bristol Myers Squibb, Palo Alto Networks, MP Materials